OBJECTIVE: To determine whether locally acting ACE-083 is safe, well tolerated, and increases muscle volume, motor function, and quality of life (QoL) in adults with Charcot-Marie-Tooth disease (CMT) type 1. METHODS: This phase 2 study enrolled adults with CMT1 or CMTX (N=63). Part 1 was open-label and evaluated safety and tolerability of different dose levels of ACE-083 for use in Part 2. Part 2 was a randomized, placebo-controlled, 6-month study of 240 mg/muscle ACE-083 injected bilaterally in the tibialis anterior muscle, followed by a 6-month, open-label extension in which all patients received ACE-083. Pharmacodynamic endpoints included total muscle volume (TMV; primary endpoint), contractile muscle volume (CMV), and fat fraction. Additional secondary endpoints included 6-minute walk test, 10-meter walk/run, muscle strength, and QoL. Safety was assessed with treatment-emergent adverse events (TEAEs) and clinical laboratory tests. RESULTS: In Part 1 (n=18), ACE-083 was generally safe and well tolerated at all dose levels, with no serious AEs, TEAEs ≥Grade 3, or death reported. In Part 2 (n=45 enrolled, n=44 treated), there was significantly greater change in TMV with ACE-083 compared with placebo (LS mean difference: 13.5%; p = 0.0096). There was significant difference between ACE-083 and placebo for CMV and change in ankle dorsiflexion strength. Fat fraction and all other functional outcomes were not significantly improved by ACE-083. Moderate-to-mild injection-site reactions were the most common TEAEs. CONCLUSIONS: Despite significantly increased TMV and CMV, patients with CMT receiving ACE-083 in tibialis anterior muscles did not demonstrate greater functional improvement compared with those receiving placebo. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that intramuscular ACE-083 is safe, well tolerated, and increases total muscle volume after 6 months of treatment in adults with CMT1 or CMTX.
OBJECTIVE: To determine whether locally acting ACE-083 is safe, well tolerated, and increases muscle volume, motor function, and quality of life (QoL) in adults with Charcot-Marie-Tooth disease (CMT) type 1. METHODS: This phase 2 study enrolled adults with CMT1 or CMTX (N=63). Part 1 was open-label and evaluated safety and tolerability of different dose levels of ACE-083 for use in Part 2. Part 2 was a randomized, placebo-controlled, 6-month study of 240 mg/muscle ACE-083 injected bilaterally in the tibialis anterior muscle, followed by a 6-month, open-label extension in which all patients received ACE-083. Pharmacodynamic endpoints included total muscle volume (TMV; primary endpoint), contractile muscle volume (CMV), and fat fraction. Additional secondary endpoints included 6-minute walk test, 10-meter walk/run, muscle strength, and QoL. Safety was assessed with treatment-emergent adverse events (TEAEs) and clinical laboratory tests. RESULTS: In Part 1 (n=18), ACE-083 was generally safe and well tolerated at all dose levels, with no serious AEs, TEAEs ≥Grade 3, or death reported. In Part 2 (n=45 enrolled, n=44 treated), there was significantly greater change in TMV with ACE-083 compared with placebo (LS mean difference: 13.5%; p = 0.0096). There was significant difference between ACE-083 and placebo for CMV and change in ankle dorsiflexion strength. Fat fraction and all other functional outcomes were not significantly improved by ACE-083. Moderate-to-mild injection-site reactions were the most common TEAEs. CONCLUSIONS: Despite significantly increased TMV and CMV, patients with CMT receiving ACE-083 in tibialis anterior muscles did not demonstrate greater functional improvement compared with those receiving placebo. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that intramuscular ACE-083 is safe, well tolerated, and increases total muscle volume after 6 months of treatment in adults with CMT1 or CMTX.
Authors: Justin L Chen; Kelly L Walton; Adam Hagg; Timothy D Colgan; Katharine Johnson; Hongwei Qian; Paul Gregorevic; Craig A Harrison Journal: Proc Natl Acad Sci U S A Date: 2017-06-12 Impact factor: 11.205
Authors: Jennifer A Tinklenberg; Emily M Siebers; Margaret J Beatka; Hui Meng; Lin Yang; Zizhao Zhang; Jacob A Ross; Julien Ochala; Carl Morris; Jane M Owens; Nigel G Laing; Kristen J Nowak; Michael W Lawlor Journal: Hum Mol Genet Date: 2018-02-15 Impact factor: 6.150
Authors: Kathryn R Wagner; James L Fleckenstein; Anthony A Amato; Richard J Barohn; Katharine Bushby; Diana M Escolar; Kevin M Flanigan; Alan Pestronk; Rabi Tawil; Gil I Wolfe; Michelle Eagle; Julaine M Florence; Wendy M King; Shree Pandya; Volker Straub; Paul Juneau; Kathleen Meyers; Cristina Csimma; Tracey Araujo; Robert Allen; Stephanie A Parsons; John M Wozney; Edward R Lavallie; Jerry R Mendell Journal: Ann Neurol Date: 2008-05 Impact factor: 10.422
Authors: Lidiane Carine Lima Santos Barreto; Fernanda Santos Oliveira; Paula Santos Nunes; Iandra Maria Pinheiro de França Costa; Catarina Andrade Garcez; Gabriel Mattos Goes; Eduardo Luis Aquino Neves; Jullyana de Souza Siqueira Quintans; Adriano Antunes de Souza Araújo Journal: Neuroepidemiology Date: 2016-02-06 Impact factor: 3.282
Authors: R S Pearsall; M V Davies; M Cannell; J Li; J Widrick; A W Mulivor; S Wallner; M E Troy; M Spaits; K Liharska; D Sako; R Castonguay; S Keates; A V Grinberg; R N V S Suragani; R Kumar Journal: Sci Rep Date: 2019-08-06 Impact factor: 4.379
Authors: Katy Eichinger; Janet E Sowden; Joshua Burns; Michael P McDermott; Jeffrey Krischer; John Thornton; Davide Pareyson; Steven S Scherer; Michael E Shy; Mary M Reilly; David N Herrmann Journal: Front Neurol Date: 2022-06-27 Impact factor: 4.086